Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2015-07-18
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of lenalidomide when given
together with combination chemotherapy in treating patients with relapsed or refractory acute
myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking
blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone hydrochloride,
etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either
by killing the cells or by stopping them from dividing. Giving lenalidomide and combination
chemotherapy may be an effective treatment for acute myeloid leukemia.